Adendra Launched To Unlock Immunotherapy Potential Of Dendritic Cells
Another Spin-Out From London’s Crick Institute
Expertise in dendritic cells could help generate new targets in cancer and autoimmune disease immunotherapy.
You may also be interested in...
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.
The Swiss pharma sees the acquisition as the ‘backbone’ for its future cardiometabolic portfolio, which could include a combination with a muscle-building therapy.